Acceleration of K+ channel inactivation by MEK inhibitor U0126

Li-Lian Yuan1, Xixi Chen, Kumud Kunjilwar

  • 1Dept. of Neuroscience, Univ. of Minnesota, 6-145 Jackson Hall, 321 Church St., Minneapolis, MN 55455, USA. yuanx033@umn.edu

Insights

The compound U0126 accelerates the inactivation of Kv4.2 potassium channels. This effect appears to be a direct action on channel gating, independent of MEK/ERK kinase inhibition.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Biophysics

Background:

  • Voltage-dependent potassium (Kv)4.2 channels regulate neuronal excitability.
  • These channels are modulated by protein kinases, notably ERK.
  • U0126 is commonly used to inhibit MEK, upstream of ERK.

Purpose of the Study:

  • To investigate the mechanism by which U0126 affects Kv4.2 channel inactivation.
  • To determine if U0126's effect on Kv4.2 channels is mediated by MEK/ERK kinase inhibition.

Main Methods:

  • Studied heterologously expressed Kv4.2 channels and Kv1.1 channels.
  • Utilized U0126 and a less potent derivative, U0125.
  • Expressed a Kv4.2 mutant lacking key ERK phosphorylation sites.

Main Results:

  • U0126 (1-20 microM) accelerated Kv4.2 inactivation time constants.
  • U0126 also induced inactivation in non-inactivating Kv1.1 currents.
  • U0125 produced similar effects on channel inactivation.
  • U0126 accelerated inactivation even in a Kv4.2 mutant lacking ERK phosphorylation sites.

Conclusions:

  • U0126 accelerates Kv4.2 channel inactivation.
  • The observed effects are independent of MEK/ERK kinase inhibition.
  • U0126 likely acts directly on Kv4.2 channel gating.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...